Engineered Probiotics as Precision Therapeutics for Epilepsy: Mechanistic Rationale and Preclinical Strategies

http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 97 Engineered Probiotics as Precision Therapeutics for Epilepsy: Mechanistic Rationale and Preclinical Strategies Ume Aymen Arshad* Institute of Molecular biology and Biotechnology, University of Lahore - Sargodha campus, Sargodha 40100, Pakistan Epilepsy is now being increasingly understood as a multi-system disease where gut microbiome dysbiosis contributes greatly to the regulation of neuronal excitability, neuroimmune with metabolic homeostasis. The new evidence shows that the changes in microbial composition especially the loss of short-chain fatty acid (SCFA) producers, GABAogenic taxa, and indole-producing commensals are linked to increase the vulnerability to seizures and chronic neuroinflammation. Programmable neuromodulatory metabolic platforms, cytokine-responsive therapeutic release, and delivery of antioxidant or neuroprotective molecules Engineered probiotics provide a new precision-therapeutic platform that has the potential to target these pathways. Synthetic biology is allowing strains to overexpress GABA, produce specific SCFAs, tune tryptophan-kynurenine, and express RNA-based regulators, which repress proinflammatory signalling. Preclinical work in pentylenetetrazole, kainate, pilocarpine and genetic epilepsy models all demonstrate a reduction in the severity of the seizures, an improvement in mitochondrial activity, and a resultant increase in the integrity of the barriers after probiotic treatment, with engineered strains performing better in efficacy and mechanism specificity than native probiotics. Innovations in safety, such as kill switches, synthetic auxotrophy, and biocontainment circuits, enhance translational capability in application to clinical use. Engineered probiotics too have a high integrative potential and form synergy with anti-seizure drugs and mimesis of the ketogenic diet by generating ketone-like or SCFA metabolites. Even with the encouraging results, large obstacles, such as inter-individual microbiome heterogeneity, small human clinical, and regulatory obstacles of genetically altered live biotherapeutics, persist. Future perspectives focus on individualized, multi-strain engineered consortia, AI-aided designing of microbial circuits, which have the potential to multi-axis modulate epileptogenic pathways. Together, engineered probiotics constitute a disruptive future of microbiome-informed precision therapy of epilepsy. Keywords: Engineered Probiotics, Epilepsy, Gut–Brain Axis, Neuroinflammation, Gaba Modulation, Short-Chain Fatty Acids, Synthetic Biology. Introduction Epilepsy is a chronic neurological disease, which is manifested by frequent random seizures due to disturbed neuronal excitability, disrupted synaptic communication, and dysregulated neuroimmune signaling. Though existing antiepileptic drugs (AEDs) A B S T R A C T http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 98 are focused on ion channels, neurotransmitter systems, or synaptic vesicles proteins, one-third of patients are pharmacoresistant, and these Whole Protein Therapeutic approaches are required to be not limited to classical neurocentric interventions. Over the last several years, there has been emerging convergent evidence that the gut and brain can communicate via a two-way communication axis, known as the gut-brain axis (GBA), which regulates neuronal excitability by means of microbial metabolites, immune pathways, and vagal signaling (1,2). The pathophysiological evidence that can be attributed to seizure susceptibility includes dysbiosis-related changes in shortchain fatty acids (SCFAs), the synthesis of gamma-aminobutyric acid (GABA), metabolites of the kynurenine pathway, and proinflammatory cytokines (3). Next-generation precision biotherapeutic platforms—engineered probiotics—can now be used to model host neurophysiology by regulated biosynthesis of neuromodulatory molecules, targeted immunomodulation, and metabolic pathway rewiring. Synthetic biology can be used to program probiotic chassis (e.g., Lactobacillus, Bifidobacterium and Escherichia coli Nissle 1917) to respond to host-derived cues (e.g., inflammatory markers, pH, lactate or bile acids) to release therapeutic payloads in spatiotemporally controlled ways. In epilepsy, artificial strains have been designed to modulate GABAergic tone, degrade excitatory glutamate, increase SCFA generation, trap proinflammatory cytokines or provide neuroprotective peptides (4,5). The objectives of these changes are to restore the excitatory/inhibitory balance of neurotransmission, reduce neuroinflammation, and normalize neuronal networks, which are key mechanistic sites of epileptogenesis. There is evidence of microbiome-targeted interventions changing seizure thresholds, decreasing neuroinflammatory load, and affecting hippocampal circuit plasticity in preclinical studies using rodent models of temporal lobe epilepsy (TLE), kainic acid– induced seizures, and gene models such as SCN1A-/- mice (6). Engineered microbial platforms also facilitate precision delivery of therapeutic agents with less systemic toxicity than conventional AEDs. Nevertheless, concerns remain regarding strain stability, horizontal gene transfer, host immune responses, and regulatory pathways for live biotherapeutic products (LBPs). Strong preclinical pipelines integrating in silico circuit design, gnotobiotic models, multi-omics profiling, and neural electrophysiology are required to translate engineered-probiotic strategies into clinically viable interventions (7). Combined, engineered probiotics present a paradigm shift to reprogram the gut–brain axis to treat epilepsy and may be considered a futuristic transition toward microbiome-informed, mechanism-based precision therapeutics. 2. Epilepsy as a Multi-System Disorder and the Gut–Brain Axis Epilepsy is increasingly recognized as a multi-system disorder that extends beyond aberrant neuronal firing to encompass profound alterations in immune function, metabolism, and gut microbial ecology (8). Evidence from metabolomics, neuroimmunology, and microbiome research demonstrates that epileptogenesis is shaped by systemic physiological networks rather than exclusively by CNS-bound mechanisms (9). Among these networks, the gut–brain axis (GBA) has emerged as a critical regulator of seizure susceptibility through continuous bidirectional communication involving neural, immune, metabolic, and endocrine pathways (10). Disruptions in gut homeostasis, including microbial dysbiosis, altered metabolite http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 99 profiles, and compromised mucosal barrier integrity, have been repeatedly observed in both clinical and preclinical epilepsy models (11,12). These findings highlight the gut microbiota as a modifiable determinant of neuronal excitability and position the GBA as a promising target for precision therapeutics, including engineered microbial interventions (13,14). Figure 1. Probiotics and gut-brain axis showing the different pathways of activation Microbiota Composition in Epilepsy Multiple human studies have identified distinctive microbial signatures in individuals with epilepsy, with the most pronounced alterations observed in drug-resistant epilepsy (DRE) (15). Common dysbiotic patterns include reduced bacterial diversity, depletion of beneficial commensals (e.g., Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii), and enrichment of pro-inflammatory taxa such as Proteobacteria, Enterobacteriaceae, Desulfovibrio, and Akkermansia (16). DRE patients frequently exhibit elevated levels of endotoxin-producing gram-negative species that promote systemic inflammation and lower seizure thresholds (17). Moreover, studies report decreased abundance of short-chain fatty acid (SCFA)- producing bacteria, particularly butyrate producers, which correlates with impaired gut barrier integrity and heightened neuroinflammatory responses (18). In pediatric epileptic syndromes, including Dravet syndrome and Lennox–Gastaut syndrome, microbial patterns often show convergence toward low-diversity, inflammationassociated communities (19). Collectively, these compositional shifts suggest that http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 100 dysbiosis contributes to epileptogenesis rather than merely reflecting diseaseassociated lifestyle or medication effects (20). Pathways of Gut–Brain Crosstalk The gut–brain axis influences CNS excitability through several mechanistic pathways, each of which is perturbed in epilepsy. 2.2.1 Neural Signaling via the Vagus Nerve The vagus nerve provides a rapid communication conduit through which gut microbes modulate central neurotransmission (21). Certain Lactobacillus species have been shown to alter GABAergic signaling by regulating GABA receptor subunit expression in brain regions such as the amygdala and hippocampus. These effects occur independently of systemic circulation, demonstrating direct microbe-to-brain neural modulation that can influence seizure susceptibility. Immune Modulation Epilepsy-associated dysbiosis drives systemic immune activation characterized by elevated IL-1β, IL-6, TNF-α, and other pro-inflammatory cytokines known to reduce seizure thresholds and promote neuronal hyperexcitability (22). These cytokines activate microglia, enhance glutamatergic transmission, and disrupt inhibitory networks. Probiotic and engineered microbial interventions can attenuate these pathways by suppressing NF-κB signaling, reducing microglial activation, and restoring immune homeostasis. Metabolic and Endocrine Pathways The microbiota generates a wide range of metabolites including SCFAs, indole derivatives, secondary bile acids, and tryptophan/kynurenine metabolites that regulate neurotransmitter synthesis, mitochondrial function, oxidative stress, and neuroinflammation (23). Reduced SCFAs, particularly butyrate, impair mitochondrial efficiency and anti-inflammatory signaling, increasing seizure susceptibility. Altered tryptophan metabolism skews kynurenine pathways toward neurotoxic derivatives, further contributing to excitotoxicity. Barrier Integrity: Gut and Blood–Brain Barrier Epileptic phenotypes often include increased intestinal permeability (“leaky gut”) and compromised blood–brain barrier (BBB) integrity (24). Dysbiosis-associated reductions in SCFA-producing bacteria weaken tight junction proteins such as occludin and claudins, facilitating translocation of endotoxins (LPS) into circulation. Elevated systemic LPS promotes microglial activation and cytokine release, amplifying CNS inflammation. Probiotic and SCFA-restoring strategies strengthen barrier integrity, thereby reducing neuroinflammatory burden. Mechanistic Possible Explanation of Probiotic-Based Therapy of Epilepsy The therapeutic potential of probiotics in epilepsy is based on their ability to regulate the underlying biological mechanisms that affect neuronal excitability, neuroimmune signaling, metabolic homeostasis, and barrier integrity (25). Probiotic strains which have been engineered or found in nature have the potential to alter biochemical http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 101 pathways which are heavily implicated in epileptogenesis, providing an alternative or an adjunct to more traditional antiseizure medications on a mechanistic basis. The fact that they can provide neuroactive metabolites, reorganize inflammatory pathways, and stabilize epithelial defenses makes probiotics a targeted approach to therapeutic intervention that can be used to simultaneously address defenses in multiple axes that regulate seizures. Seizure Modulation and Microbial Metabolites Short-Chain Fatty Acids (SCFA) The SCFAs, which are mostly acetate, propionate, and butyrate, are at the center stage of neuron excitability and neuroinflammation (26). Butyrate among them has prominent anticonvulsant properties due to: the inhibition of histone deacetylase (HDAC) that increases the activity of neuroprotective and anti-inflammatory genes (27); enhancement of mitochondrial bioenergetics, ATP synthesis, and mitigation of ROS accumulation in hyperexcitable neurons (28); and improvement of GABAergic signaling, which indirectly increases inhibitory neurotransmission (29). This is because reduction of SCFA-producing microbes due to dysbiosis leads to a metabolic environment conducive to seizures, and the restoration of SCFAs through probiotics leads to the restoration of neurochemical stability (30). GABA Production A number of Lactobacillus and Bifidobacterium strains carry the glutamate decarboxylase (GAD) pathway, which facilitates an effective glutamate-to-GABA conversion. The gut-brain axis can be affected by an increased production of microbial GABA in: Enteric GABA receptor activation regulating vagal afferent firing patterns Systemic inhibitory tone improvement through peripheral-central signaling loops. Lessening of luminal glutamate reducing its excitatory portion to peripheral nerve activation and systemic excitotoxicity This type of microbial augmentation of the GABA-glutamate balance is a direct mechanistic pathway to reduce the risk of seizures (26,27). Tryptophan Metabolism Probiotics have a significant impact on the tryptophan-kynurenine pathway, which is a major metabolic pathway associated with excitotoxicity. The imbalance in tryptophan metabolism during dysbiosis favors neurotoxic metabolites like quinolinic acid, an agonist to the NMDA receptor, and is related to increased seizure susceptibility. Probiotic modulation influences the metabolic flux toward neuroprotective indole products and serotonin pathways, thus lowering the load of kynurenine-based excitotoxins (28). Neuroimmune and Epigenetic Regulation The connection between epileptogenesis and chronic neuroinflammation is strong, where prolonged inflammatory signaling provides an environment conducive to seizure onset and spread. Probiotics were found to regulate numerous inflammatory pathways to reduce this process. They suppress key signaling pathways (NF-κB and http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 102 MAPK) (29), reducing the production of proconvulsant cytokines such as IL-1β, IL-6, and TNF-α. Probiotics also inhibit hyperactivation of microglia, restricting the subsequent action of cytokines on glutamatergic neurotransmission, while stimulating anti-inflammatory cytokines including IL-10, which facilitates immune regulation and stabilizes neuronal networks (30). Metabolites produced by probiotics, including SCFAs, are also involved in epigenetic regulation via HDAC inhibition to reorganize transcriptional states, promoting neuroprotection and synaptic stability. Together, these processes help decrease inflammatory amplification loops that increase seizure susceptibility (26–30). Figure 2 Immune and inflammation paths of signaling from gut-brain axis The barriers to intestinal epithelium and the blood-brain barrier (BBB) are often impaired in epilepsy, allowing translocation of endotoxins and circulating proinflammatory molecules that reduce the seizure threshold (31). Probiotics improve barrier function in multiple ways: they stimulate the expression of tight junction proteins, including occludin, claudins, and ZO-1 in the mucosa of the gut and BBB http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 103 endothelium; increase epithelial metabolism via SCFA-mediated mucosal repair; reduce the release of lipopolysaccharide (LPS) and other endotoxins that elicit microglial activation; and normalize endothelial nitric oxide signaling, enhancing BBB resistance to inflammation. Barrier integrity is restored, preventing systemic inflow of proconvulsant molecules into the CNS, decreasing neuroinflammatory load and seizure susceptibility (32). Recent technological progress in synthetic biology has been used to design probiotic strains, including E. coli Nissle 1917, Lactococcus lactis, Lactobacillus reuteri, and Bifidobacterium breve, to perform highly specific therapeutic functions (33). These engineered microbes can be programmed to tune inflammatory signaling, generate neuroactive metabolites, enhance barrier function, or deposit neuroprotective molecules in a controlled, precise, and context-dependent environment, providing a transformative platform for microbiome-based precision therapy in epilepsy. Probiotic-Based Epilepsy Therapy Strategies in Engineering Engineering Strategies Synthetic biology can be used to rationally design probiotics to regulate key neurobiological pathways involved in epileptogenesis. Programmed engineered strains can overexpress γ-aminobutyric acid (GABA) via increased expression of the glutamate decarboxylase (GAD) operon, directly enhancing inhibitory neurotransmission (34). Similarly, strains can be engineered to produce specific shortchain fatty acids (SCFAs), especially butyrate, to precisely modulate epigenetic and mitochondrial pathways with anticonvulsant effects (35). Another emerging strategy is building inflammatory biosensors that detect increased cytokines (e.g., IL-1, TNFα) and respond by releasing anti-inflammatory molecules, neuroprotective peptides, or small-molecule modulators on demand (36). Antioxidant enzymes (including superoxide dismutase or catalase) or neuroprotective peptides can also be incorporated into engineered probiotics to counteract oxidative stress and neuronal death associated with chronic epilepsy. Advanced systems may use RNA-based modulators, such as small interfering RNAs or antisense transcripts, to locally silence pro-inflammatory gene expression in the gut or peripheral immune compartments. These programmable capabilities enable engineered probiotics to coordinate multiaxis neuromodulation beyond the capabilities of traditional antiseizure medications (ASMs) (37). Conclusion Engineered probiotics are an emergent potent therapeutic approach that can be viewed as the next generation of precision therapeutics with the capability to engage multiple epileptogenic pathways at once with targeted metabolic, immunological, and neurochemical therapies. Through synthetic biology, these strains can be programmed in order to overexpress GABA, produce useful SCFAs, detect inflammatory signals, mend damaged barriers, and release neuroprotective molecules in a highly specific and low-toxicity manner. Huge improvements in the severity of seizures, neuroinflammation, and cell death in various animal models consistently provide preclinical evidence that engineered probiotics are a revolution in addition to traditional anti-seizure therapy and ketogenic diet interventions. Nonetheless, http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 104 systematic dosing models, high-tech biocontainment platforms, and customized therapeutic plans based on patient-specific microbiome and multi-omics responses will be needed to achieve successful clinical translation. By developing engineered probiotics and incorporating them into multi-modal treatment platforms, there is an opportunity to radically re-organize the management of epilepsy using safe, flexible, and mechanistic based interventions that address the disorder both at the gut and brain level. References Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota–gut–brain axis. Physiol Rev. 2019;99(4):1877–2013. Peng A, Qiu X, Lai W, et al. Altered composition of the gut microbiome in patients with drug-resistant epilepsy. Epilepsy Res. 2018;147:102–107. Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018;173(7):1728–1741. Gülland F. The role of short‐chain fatty acids in neuroimmune signaling. Nat Rev Immunol. 2020;20:213–229. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461–478. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids in gut–brain communication. Front Endocrinol. 2020;11:25. Thion MS, Low D, Silvin A. Microbiome influences on microglia. Nat Neurosci. 2018;21:1525–1536. Bravo JA, Forsythe P, Chew MV, et al. Lactobacillus regulates emotional behavior and GABA receptors via the vagus nerve. PNAS. 2011;108(38):16050–16055. Bercik P, Collins SM. The effects of inflammation and microbiota on the enteric nervous system. Neurogastroenterol Motility. 2014;26:3–10. Vezzani A, Balosso S, Ravizza T. Neuroinflammation and epilepsy. Nat Rev Neurol. 2019;15(8):482–496. Dey A, Hankey-Giblin PA. Pro-inflammatory cytokines and seizure modulation. J Neuroinflammation. 2021;18:276. Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The gut–brain axis and neurological disease. Nat Neurosci. 2016;19(12):1513–1520. Clarke G, Stilling RM, Kennedy PJ, Cryan JF, Dinan TG. Minireview: gut microbiota and SCFA signaling. Mol Endocrinol. 2014;28:1221–1238. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism. Cell Host Microbe. 2018;23:716–724. Schwarcz R, Stone TW. The kynurenine pathway and neurodegeneration. Nat Rev Neurosci. 2017;18:593–604. Hsiao EY, McBride SW, Hsien S, et al. The microbiota modulates gut barrier and behavior. Cell. 2013;155(7):1451–1463. Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood–brain barrier permeability. Sci Transl Med. 2014;6:263ra158. Ma Q, Xing C, Long W, et al. Impact of microbiota on neuroinflammation. Cell Mol Life Sci. 2019;76:2573–2587. http://amresearchreview.com/index.php/Journal/about Volume 3, Issue 12 (2025) Online ISSN Print ISSN . . 3007-3197 3007-3189 http://amresearchreview.com/index.php/Journal/about Page 105 Anderson RC, Cookson AL, et al. Lactobacillus effects on tight-junction proteins. J Nutr. 2010;140(9):1613–1618. Rossi M, Amaretti A, Raimondi S. Engineering probiotics for therapeutic applications. Trends Biotechnol. 2021;39(8):810–822. Vargason AM, Anselmo AC, Mitragotri S. Synthetic biology applications in engineered probiotics. ACS Pharmacol Transl Sci. 2020;3(1):1–15. Mimee M, Tucker AC, Voigt CA, Lu TK. Programming gut bacteria for therapeutics. Science. 2015;347(6227):621–626. Chowdhury S, Castro S, Coker C, et al. Engineered probiotics for disease treatment. Nat Commun. 2019;10:5380. Charbonneau MR, Isabella VM, Li N, Kurtz CB. Synthetic biology in the microbiome. Curr Opin Gastroenterol. 2020;36(1):3–12. Komanduri M, Gondalia S, et al. Probiotics modulation of inflammation in epilepsy. Front Neurol. 2020;11:190. de Caro C, Leo A, Nesci V, et al. Short-chain fatty acids in seizure control. Front Cell Neurosci. 2021;15:701965. Wu J, Wang K, et al. Tryptophan metabolism and epilepsy. Int J Mol Sci. 2020;21:876. Turner JR. Intestinal mucosal barrier function. Nat Rev Immunol. 2009;9:799–809. Chen H, Wang Y, et al. Engineered probiotics improve epithelial barrier. Microbiome. 2022;10:50. Devlin AS, Fischbach MA. Engineering microbial metabolism. Cell. 2015;163:426– 439. Ruta L, Gaburro S, et al. Gut microbiota and ketogenic diet in epilepsy. Nutrients. 2021;13:2514. Kang DW, Adams JB, et al. Microbiota transfer therapy and neurological improvement. Microbiome. 2017;5:10. Pilla R, Perry E, et al. Microbial GABA production. Appl Environ Microbiol. 2021;87:e01730-20. Dinan TG, Cryan JF. Mood microbiome and metabolites. Science. 2017;358:1352– 1357. Durack J, Lynch SV. The gut microbiome and chronic disease. J Clin Invest. 2019;129(9):3730–3740. Vendrik KEW, et al. Probiotics for neurological disorders: systematic review. Neurosci Biobehav Rev. 2020;113:491–507. Sampson TR, Mazmanian SK. Control of brain development and behavior by microbial metabolites. Nat Rev Neurosci. 2015;16:341–352.